Publications by authors named "Delphine Issard"
Background: No evidence of disease activity (NEDA-3) is a patient-centric outcome increasingly used as the goal of multiple sclerosis treatment.
Objective: Determine treatment durability of cladribine tablets beyond 2 years considering the variable bridging interval of 0.1-116.
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
J Neurol Neurosurg Psychiatry
April 2017
Article Synopsis
- Early treatment with subcutaneous interferon β-1a following a first clinical demyelinating event reduces future disease activity in multiple sclerosis patients compared to delayed treatment.
- A study involving patients who completed the REFLEX trial showed that those who started early treatment had a lower probability of developing clinically definite MS and showed less MRI activity over 60 months.
- Both treatment regimens were well tolerated, with early treatment resulting in fewer patients developing antibodies against the medication.
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
J Neurol Neurosurg Psychiatry
November 2015
Aim: An exploratory study of the relationship between cumulative exposure to subcutaneous (sc) interferon (IFN) β-1a treatment and other possible prognostic factors with long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).
Methods: Patients in the original PRISMS study were invited to a single follow-up visit 15 years after initial randomisation (PRISMS-15). Outcomes over 15 years were compared in the lowest and highest quartile of the cumulative sc IFN β-1a dose groups, and according to total time receiving sc IFN β-1a as a continuous variable per 5 years of treatment.
Background: The IMPROVE study demonstrated that the fetal bovine serum (FBS)- and human serum albumin (HSA)-free formulation of subcutaneous (sc) interferon (IFN) beta-1a had beneficial effects on the numbers of combined unique active magnetic resonance imaging (MRI) lesions in relapsing-remitting multiple sclerosis (RRMS). Here we report additional MRI endpoints (including post hoc analyses), and clinical efficacy, safety, and immunogenicity outcomes.
Methods: Patients with active RRMS were randomized (2:1) to IFN beta-1a, 44 mcg sc three times weekly (tiw) (n=120), or placebo (n=60), for 16 weeks (double-blind phase).
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n = 180) were randomized (2 : 1) to IFN-beta1a or placebo for 16 weeks; all patients then received IFN-beta1a for 24 weeks. Monthly brain MRI was performed.
View Article and Find Full Text PDF